Stock HBP HELIX BIOPHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Helix BioPharma Corp.

Equities

HBP

CA4229101098

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 07:36:40 13/05/2024 pm IST 		5-day change 1st Jan Change
0.23 CAD 0.00% Intraday chart for Helix BioPharma Corp. +4.55% +9.52%
08/04 Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding CI
28/03 Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding CI

Valuation

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Capitalization 1 71.97 62.29 71.78 117.1 32.64 42
Enterprise Value (EV) 1 71.6 62.08 67.71 117.2 31.86 41.2
P/E ratio -7.78 x -7.94 x -7.68 x -14.2 x -4.33 x -6.45 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -8.54 x -8.43 x -7.91 x -12.9 x -5.28 x -6.53 x
EV / FCF -16.4 x -22.8 x -9.49 x -24.4 x -7.51 x -18.7 x
FCF Yield -6.11% -4.39% -10.5% -4.1% -13.3% -5.35%
Price to Book -47.1 x -19 x 30 x -84.1 x 102 x -49.8 x
Nbr of stocks (in thousands) 1,02,810 1,11,226 1,32,933 1,41,133 1,71,795 2,00,019
Reference price 2 0.7000 0.5600 0.5400 0.8300 0.1900 0.2100
Announcement Date 26/10/18 25/10/19 29/10/20 09/12/21 31/10/22 27/10/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -8.381 -7.367 -8.56 -9.072 -6.028 -6.313
EBIT 1 -8.546 -7.492 -8.616 -9.131 -6.04 -6.326
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -8.625 -7.526 -8.561 -9.574 -6.563 -6.29
Net income 1 -8.625 -7.526 -8.985 -8.038 -6.563 -6.29
Net margin - - - - - -
EPS 2 -0.0900 -0.0706 -0.0704 -0.0583 -0.0439 -0.0326
Free Cash Flow 1 -4.371 -2.727 -7.134 -4.801 -4.242 -2.204
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 26/10/18 25/10/19 29/10/20 09/12/21 31/10/22 27/10/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 0.05 - -
Net Cash position 1 0.37 0.21 4.08 - 0.78 0.81
Leverage (Debt/EBITDA) - - - -0.005181 x - -
Free Cash Flow 1 -4.37 -2.73 -7.13 -4.8 -4.24 -2.2
ROE (net income / shareholders' equity) 1,117% 313% 5,707% -1,206% 1,222% 2,396%
ROA (Net income/ Total Assets) -320% -449% -184% -127% -96.9% -166%
Assets 1 2.692 1.677 4.877 6.318 6.776 3.786
Book Value Per Share 2 -0.0100 -0.0300 0.0200 -0.0100 0 -0
Cash Flow per Share 2 0 0 0.0300 0.0300 0.0200 0
Capex 1 0.05 0 0.02 - - 0.01
Capex / Sales - - - - - -
Announcement Date 26/10/18 25/10/19 29/10/20 09/12/21 31/10/22 27/10/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HELIX BIOPHARMA CORP. Stock Helix BioPharma Corp.
+9.52% 38.63M
MODERNA, INC. Stock Moderna, Inc.
+26.37% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.01% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+46.00% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.34% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.23% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.99% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.38% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HBP Stock
  4. Financials Helix BioPharma Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW